Standard Dosage for Small Cell Lung Cancer
Lurbinectedin ( Zepzelca) is FDA-approved for metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. The recommended dose is 3.2 mg/m² administered intravenously over 60 minutes on Day 1 of a 21-day cycle.[1][2]
Dosage Administration and Premedication
Give as monotherapy. Premedicate with corticosteroids (e.g., dexamethasone 10 mg IV 30 minutes before), antiemetics (e.g., 5-HT3 antagonist plus dexamethasone), and antihistamines (e.g., H1 blocker like ranitidine, H2 blocker like diphenhydramine) to prevent hypersensitivity and nausea.[1][2] No routine prophylactic G-CSF unless neutropenia risk factors exist.
Dosage Adjustments for Toxicity
Reduce dose for adverse reactions:
- Myelosuppression: First occurrence of grade 4 neutropenia/neutropenic fever or grade 3 thrombocytopenia → hold until recovery to grade 1 or less, then 2.6 mg/m² (20% reduction). Second → 2.0 mg/m² (40% reduction). Third → discontinue.
- Hepatotoxicity: Grade 3/4 → hold until recovery to grade 1 or less, then 2.6 mg/m².
- Other non-hematologic grade 3/4: Hold until recovery, then 2.6 mg/m².[1][2]
| Adverse Event | Grade 3/4 Occurrence | Action |
|---------------|----------------------|--------|
| Neutropenia or Febrile Neutropenia | 1st | Hold, then 2.6 mg/m² |
| | 2nd | 2.0 mg/m² |
| | 3rd | Discontinue |
| Thrombocytopenia (Grade 3) | 1st | Hold, then 2.6 mg/m² |
| Transaminase Increase | Grade 3/4 | Hold, then 2.6 mg/m² |
Monitor CBC weekly, liver function before each cycle. Delay if platelets <100,000/µL or ANC <1,500/µL.
Dosage in Special Populations
- Renal/Hepatic Impairment: No adjustment for mild-moderate renal (CrCl ≥30 mL/min); avoid severe renal. Mild hepatic (bilirubin ≤ULN, AST >ULN) → no change; moderate-severe → not studied, avoid.[1][2]
- Elderly: No specific adjustments, but higher toxicity risk.
- Pediatrics: Safety/efficacy not established.
Investigational Uses and Off-Label Dosing
In trials for other cancers (e.g., pleural mesothelioma, breast, ovarian), doses range 3.0-3.5 mg/m² every 21 days or 2.0 mg/m² days 1+8 every 21 days, often combined with doxorubicin or irinotecan. Always follow trial protocols; consult oncologist for non-SCLC use.[3]
Sources
[1]: Zepzelca Prescribing Information (FDA)
[2]: Drugs.com - Lurbinectedin Dosage
[3]: ClinicalTrials.gov - Lurbinectedin Studies